Cargando…

The Efficacy and Safety of Remimazolam Besylate Combined with Esketamine for Outpatient Colonoscopy: A Prospective, Randomized, Controlled Clinical Trial

PURPOSE: Evaluate the efficacy and safety of remimazolam besylate combined with esketamine for outpatient colonoscopy. PATIENTS AND METHODS: A total of 150 outpatients undergoing colonoscopy were randomized into two groups. A MOAA/S score ≤3 was maintained. The primary outcome was the rate of succes...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wei, Zhao, Jun, Hao, Ruiping, Wang, Shujuan, Chen, Ming, Liu, Huijun, Qi, Le, Hao, Zaijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516197/
https://www.ncbi.nlm.nih.gov/pubmed/37746114
http://dx.doi.org/10.2147/DDDT.S425860
_version_ 1785109088352337920
author Li, Wei
Zhao, Jun
Hao, Ruiping
Wang, Shujuan
Chen, Ming
Liu, Huijun
Qi, Le
Hao, Zaijun
author_facet Li, Wei
Zhao, Jun
Hao, Ruiping
Wang, Shujuan
Chen, Ming
Liu, Huijun
Qi, Le
Hao, Zaijun
author_sort Li, Wei
collection PubMed
description PURPOSE: Evaluate the efficacy and safety of remimazolam besylate combined with esketamine for outpatient colonoscopy. PATIENTS AND METHODS: A total of 150 outpatients undergoing colonoscopy were randomized into two groups. A MOAA/S score ≤3 was maintained. The primary outcome was the rate of successful colonoscopy completion. Time indicators, hemodynamic parameters, the consumption of lidocaine, esketamine, propofol and remimazolam besylate, MOAA/S scores and bispectral index (BIS) values, the lowest SpO(2), body movement, the use of rescue medication, endoscopist and patient satisfaction, recall of the procedure, mini-mental state examination (MMSE), fatigue level and adverse events were recorded. RESULTS: Procedure completion was equivalent between groups (P > 0.05). Both induction and awakening times were significantly shorter in the P group (P < 0.05). There were no significant differences in colonoscopy time and discharge time (P > 0.05). The lowest SpO(2) was significantly lower in the P group, while the level of fatigue was higher (P < 0.05). Patient satisfaction was significantly higher in the R group (P < 0.05). Endoscopist satisfaction was significantly higher in the P group (P < 0.05). There were no significant differences in both systolic and diastolic blood pressure between groups except at T5 and T6 (P > 0.05). Both HR and RR were significantly lower in the P group from T3 to T5 (P < 0.05). BIS values were significantly lower in the P group from T3 to T5, while MOAA/S was significantly lower in the P group at T3 and T4 (P < 0.05). Pain on injection was significantly higher in the P group (P < 0.05). CONCLUSION: Remimazolam besylate has a similar efficacy to propofol when combined with subanesthetic doses of esketamine during outpatient colonoscopy. Remimazolam besylate combined with esketamine resulted in less injection pain and more stable hemodynamics, although it prolonged induction and awakening time.
format Online
Article
Text
id pubmed-10516197
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-105161972023-09-23 The Efficacy and Safety of Remimazolam Besylate Combined with Esketamine for Outpatient Colonoscopy: A Prospective, Randomized, Controlled Clinical Trial Li, Wei Zhao, Jun Hao, Ruiping Wang, Shujuan Chen, Ming Liu, Huijun Qi, Le Hao, Zaijun Drug Des Devel Ther Original Research PURPOSE: Evaluate the efficacy and safety of remimazolam besylate combined with esketamine for outpatient colonoscopy. PATIENTS AND METHODS: A total of 150 outpatients undergoing colonoscopy were randomized into two groups. A MOAA/S score ≤3 was maintained. The primary outcome was the rate of successful colonoscopy completion. Time indicators, hemodynamic parameters, the consumption of lidocaine, esketamine, propofol and remimazolam besylate, MOAA/S scores and bispectral index (BIS) values, the lowest SpO(2), body movement, the use of rescue medication, endoscopist and patient satisfaction, recall of the procedure, mini-mental state examination (MMSE), fatigue level and adverse events were recorded. RESULTS: Procedure completion was equivalent between groups (P > 0.05). Both induction and awakening times were significantly shorter in the P group (P < 0.05). There were no significant differences in colonoscopy time and discharge time (P > 0.05). The lowest SpO(2) was significantly lower in the P group, while the level of fatigue was higher (P < 0.05). Patient satisfaction was significantly higher in the R group (P < 0.05). Endoscopist satisfaction was significantly higher in the P group (P < 0.05). There were no significant differences in both systolic and diastolic blood pressure between groups except at T5 and T6 (P > 0.05). Both HR and RR were significantly lower in the P group from T3 to T5 (P < 0.05). BIS values were significantly lower in the P group from T3 to T5, while MOAA/S was significantly lower in the P group at T3 and T4 (P < 0.05). Pain on injection was significantly higher in the P group (P < 0.05). CONCLUSION: Remimazolam besylate has a similar efficacy to propofol when combined with subanesthetic doses of esketamine during outpatient colonoscopy. Remimazolam besylate combined with esketamine resulted in less injection pain and more stable hemodynamics, although it prolonged induction and awakening time. Dove 2023-09-18 /pmc/articles/PMC10516197/ /pubmed/37746114 http://dx.doi.org/10.2147/DDDT.S425860 Text en © 2023 Li et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Li, Wei
Zhao, Jun
Hao, Ruiping
Wang, Shujuan
Chen, Ming
Liu, Huijun
Qi, Le
Hao, Zaijun
The Efficacy and Safety of Remimazolam Besylate Combined with Esketamine for Outpatient Colonoscopy: A Prospective, Randomized, Controlled Clinical Trial
title The Efficacy and Safety of Remimazolam Besylate Combined with Esketamine for Outpatient Colonoscopy: A Prospective, Randomized, Controlled Clinical Trial
title_full The Efficacy and Safety of Remimazolam Besylate Combined with Esketamine for Outpatient Colonoscopy: A Prospective, Randomized, Controlled Clinical Trial
title_fullStr The Efficacy and Safety of Remimazolam Besylate Combined with Esketamine for Outpatient Colonoscopy: A Prospective, Randomized, Controlled Clinical Trial
title_full_unstemmed The Efficacy and Safety of Remimazolam Besylate Combined with Esketamine for Outpatient Colonoscopy: A Prospective, Randomized, Controlled Clinical Trial
title_short The Efficacy and Safety of Remimazolam Besylate Combined with Esketamine for Outpatient Colonoscopy: A Prospective, Randomized, Controlled Clinical Trial
title_sort efficacy and safety of remimazolam besylate combined with esketamine for outpatient colonoscopy: a prospective, randomized, controlled clinical trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516197/
https://www.ncbi.nlm.nih.gov/pubmed/37746114
http://dx.doi.org/10.2147/DDDT.S425860
work_keys_str_mv AT liwei theefficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial
AT zhaojun theefficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial
AT haoruiping theefficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial
AT wangshujuan theefficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial
AT chenming theefficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial
AT liuhuijun theefficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial
AT qile theefficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial
AT haozaijun theefficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial
AT liwei efficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial
AT zhaojun efficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial
AT haoruiping efficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial
AT wangshujuan efficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial
AT chenming efficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial
AT liuhuijun efficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial
AT qile efficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial
AT haozaijun efficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial